Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use

Henrieta Fraser, Edward Samuel, Sarah Thirkell et al.|Cancer Research|2020

Cited by 0